Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in combination with antineoplastic agents for B-cell non-Hodgkin lymphoma
NL-OMON60181Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab and lenalidomide in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more, sponsored by AbbVie Inc. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
epcoritamablenalidomide
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON60181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60181.